COLL COLLEGIUM PHARMACEUTICAL
Permanent stock page ↗Health Care · Russell 2000
Next earnings: not announced yet
What 9 analyst firms say about COLLEGIUM PHARMACEUTICAL: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 6 months
Analyst view · last 6M
8 rated views · 9 analyst/firm records · 9 firms
Radar score
- Russell 2000 · Top Picks · 6MGood · #82 in the index82
- Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8061
Recent analyst activity · last 90 days
Our tracked history has 7 reports on COLL from 7 analyst firms in the last 90 days (10 firms in the past year).
Comparing each firm's latest target with its previous one: 1 raised its price target, 2 lowered it and 2 have their first observed target in the past year.
No firm's latest available rating differs from its previous one.
Latest observed target change: Needham lowered its target from $46.00 (set 6 Aug 2026) to $44.00 on 5 Nov 2026.
Last 6 months. Latest opinion per identifiable analyst within the last 6 months. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Barclays | Glen Santangelo | Buy | 19 Aug 2026 | 48.00 USD |
| H.C. Wainwright | Brandon Folkes | Buy | 7 Aug 2026 | 60.00 USD |
| Leerink Partners | Daniel Clark | Buy | 9 Sep 2026 | 45.00 USD |
| Needham | Serge Belanger | Buy | 6 Aug 2026 | 46.00 USD |
| Oppenheimer | Les Sulewski | Buy | 23 Sep 2026 | 50.00 USD |
| Piper Sandler | David Amsellem | Hold | 7 Aug 2026 | 43.00 USD |
| Truist | Alexander Xenakis | Buy | 9 Sep 2026 | 49.00 USD |
| Weiss Ratings | Unnamed analyst | — | 4 Sep 2026 | — |
| Data feed RESEARCH | Research Team | Buy | 15 Oct 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 03:13 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.